Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)

Next Previous
X
Search
Trial Profile

A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Soticlestat (Primary) ; Soticlestat (Primary)
  • Indications Dravet syndrome; Lennox-Gastaut syndrome
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ENDYMION 2
  • Sponsors Takeda; Takeda Development Center Americas

    • Most Recent Events

    • 23 Jun 2023 Planned number of patients changed from 376 to 400.
    • 17 Feb 2023 Planned End Date changed from 8 Jun 2025 to 22 May 2026.
    • 17 Feb 2023 Planned primary completion date changed from 8 Jun 2025 to 22 May 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top